novo_nordisk_new_hillerod_facility

Novo Nordisk expands in Denmark

pharmafile | September 8, 2015 | News story | Manufacturing and Production, Research and Development Denmark, Novo Nordisk, haemophilia API 

Novo Nordisk has announced that the company is investing 500 million Danish kroner (about £48.8 million) in a new 19,000 sqm warehouse in Hillerød, Denmark. Novo Nordisk’s site in Hillerød currently has about 1,900 employees and 70 staff will work in the new warehouse.

The warehouse will handle all inbound raw materials for Novo Nordisk’s production in Denmark and will have a capacity of around 17,000 pallets.

Susanne Hundsbæk-Pedersen, senior vice president of Devices & Supply Chain Management at Novo Nordisk, says: “The investment in Hillerød underpins our long-term plans to invest in Denmark. Hillerød is a strategic site in Novo Nordisk and we’re consolidating our inbound flow of materials at this site.”

Groundbreaking took place on September 3 and the warehouse is expected to be fully operational by the end of 2017. 

Advertisement

The current Hillerød site is used for production and R&D facilities and encompasses a facility for Device R&D and three production facilities: one for moulding and pre-assembly of components, one for filling, assembly and packaging of finished diabetes products and another for production of haemophilia API.

The collaboration will establish a number of research positions to be hosted by the Langer Laboratory and funded by Novo Nordisk. The initial term of the collaboration is three years, with the option to extend for up to three additional years.

Yasmita Kumar

Related Content

hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation

BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …

The Gateway to Local Adoption Series

Latest content